Gilead Sciences, Inc. (GILD)
Healthcare · Drug Manufacturers - General · Data as of 2026-10-22
Bottom line
GILD is trading at a premium to its history, in the middle of its recent price range, and recent volume shows no clear direction. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Expensive against its own asset value (Red)
GILD is losing money, so we lean on its balance sheet: price-to-book of 16.4× versus its own typical 4.8×. Day-to-day operations still generate cash (EV/EBITDA 162.8×), so the losses come from costs like interest and depreciation rather than the core business. Despite the accounting losses, it already generates positive free cash flow. Analysts currently expect it to turn profitable around 2027.
Price zones — In the middle of its recent range (Yellow)
At $157.19, the stock sits between its recent support and resistance levels. Over the past year GILD has traded between $114.02 and $160.51; its historical support zone sits near $148.48 and resistance near $160.51. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $114.02–$160.51 · 50-day average $148.48 · 200-day average $138.71
Money flow — No clear direction (Yellow)
Buying and selling volume in GILD have been fairly balanced recently, with no strong accumulation or distribution pattern. Volume on up days has been about 0.8× volume on down days over the last 30 sessions.
Dividends & company facts
GILD paid $3.25 a share in dividends over the past year — 2.1% of today's price — and has raised it in each of the last five years. It also bought back shares: $1.5 billion in fiscal 2025, about 0.78% of its market value.
- Dividend yield (12 months)
- 2.07%
- Paid over 12 months
- $3.25 a share
- Buybacks
- 0.78% (fiscal 2025)
- Shares, past year
- -1.0%
- Revenue, 12 months
- $30.5B
- Profit, 12 months
- $-3240M
- Employees
- 17,000
- CEO
- Daniel O'Day
- Headquarters
- Foster City, CA
- Listed since
- 1992 · NASDAQ
About the company
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs.
Related stocks
一句话结论
GILD 相对自身历史处于溢价水平，处于近期价格区间的中部，近期成交量没有明确方向。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 相对自身资产价值偏高
GILD 目前处于亏损，因此我们更多地看资产负债表：市净率为 16.4×，而它自身惯常的水平是 4.8×。日常经营仍在产生现金（EV/EBITDA 为 162.8×），因此亏损来自利息、折旧这类成本，而非核心业务本身。尽管账面上是亏损，它已经能产生正的自由现金流。分析师目前预计它将在 2027 年前后转为盈利。
价格区间 — 处于近期区间的中部
目前价格为 $157.19，位于其近期的支撑位与阻力位之间。过去一年 GILD 的价格在 $114.02 到 $160.51 之间波动；其历史支撑区在 $148.48 附近，阻力区在 $160.51 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 方向不明确
GILD 近期的买卖成交量大致均衡，没有明显的吸筹或派发形态。过去 30 个交易日，上涨日的成交量约为下跌日的 0.8×。
股息与公司概况
GILD 过去一年每股派息 3.25 美元，相当于当前股价的 2.1%，过去五年每年都有上调。它也回购了股票：2025 财年回购 15.1亿美元，约占市值的 0.78%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.